A randomized, double-blind, placebo-controlled Phase II Efficacy and Safety Study of the PDE10A inhibitor PF-02545920 in Huntington Disease (AMARYLLIS)
Objective: To assess efficacy on motor function, safety and tolerability of the phosphodiesterase-10A inhibitor PF-02545920 in Huntington disease (HD). Conclusion: PF-02545920 was generally safe and…A comprehensive digital biomarker active testing and passive monitoring suite for the remote and frequent assessment of motor symptom progression in Parkinson’s disease
Objective: We present the development and design of a comprehensive digital biomarker smartphone application (app) for remote and frequent assessments of motor symptom severity and…Evaluating Parkinsonian motor features via the routine use of consumer electronics – neuroQWERTY
Objective: Our goal was to evaluate the validity and reproducibility of a novel metric, neuroQWERTY index (nQi), to characterize PD's motor component. Background: The motor…